Co-management of exudative AMD with Avastin and Doxycycline
Phase 1
- Conditions
- wet Age related Macular Degeneration.Degeneration of macula and posterior pole
- Registration Number
- IRCT2015020921017N1
- Lead Sponsor
- Vice Chancellor for Research and Technology, Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
occult choroidal neovascularization (classic CNV); subfoveal age related macular degeneration; naïve patients; central retinal thickness plus subfoveal fluid = 500 µm; lesion size = 2 Disk Diameter; no history for neither systemic disease nor myocardial infarction
Exclusion criteria: vitreomacular adhesion; fibrovascular scar; geographic atrophy; history of intraocular pressure rise.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Induction time. Timepoint: monthly after initiation of intervention. Method of measurement: Questionnaire.;Number of needed injections to complete Induction phase. Timepoint: monthly after initiation of intervention. Method of measurement: Questionnaire.
- Secondary Outcome Measures
Name Time Method Final Best Corrected Visual Acuity (BCVA). Timepoint: 12 months after initiation of intervention. Method of measurement: Early Treatment Diabetic Retinopathy Study (ETDRS) charts.;Size of neovascularization. Timepoint: 12 months after initiation of intervention. Method of measurement: Questionnaire.;Foveal thickness. Timepoint: 12 months after initiation of intervention. Method of measurement: Questionnaire, Optical Coherence Tomography (OCT) records.;Relapse: new onset of Intraretinal fluid, Subretinal fluid, Hemorrhage or decrease of BCVA more than 5 scores). Timepoint: 12 months after initiation of intervention. Method of measurement: Questionnaire: physical examination, OCT scan, ETDRS Charts.